Neuropace Stock Investor Sentiment

NPCE Stock  USD 12.30  0.07  0.57%   
About 58% of all Neuropace's shareholders are looking to take a long position. The analysis of overall sentiment of trading Neuropace stock suggests that some investors are interested at this time. The current market sentiment, together with Neuropace's historical and current headlines, can help investors time the market. In addition, many technical investors use Neuropace stock news signals to limit their universe of possible portfolio assets.

Comfort Level 58

 Interested

 
Panic
 
Confidence
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Neuropace's input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Neuropace.

Neuropace Historical Sentiment

Although Neuropace's investment sentiment alone cannot always predict changes in its future share prices, when combined with other fundamental and technical analysis, a better chance to time the market can be gained. Certain informational and emotional events regarding Neuropace, such as negative comments on social media and news outlets, may cause fear in the market and push Neuropace's investors to sell their holdings. The opposite can also be true when favorable news is released; it may translate into optimism and boost the price of Neuropace.
  

Neuropace Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Neuropace can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Neuropace Historical Investor Sentiment

Investor biases related to Neuropace's public news can be used to forecast risks associated with an investment in Neuropace. The trend in average sentiment can be used to explain how an investor holding Neuropace can time the market purely based on public headlines and social activities around Neuropace. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Neuropace's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Neuropace and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Neuropace news discussions. The higher the estimate score, the more favorable the investor's outlook on Neuropace.
2 days ago at news.google.com         
NeuroPace, Inc. Short Interest Up 25.5 percent in March - MarketBeat
Google News at Macroaxis
few days ago at globenewswire.com         
NeuroPace Announces Upcoming Oral Presentation of Data from the Long-Term Post-Approval Study of the...
Macroaxis News: globenewswire.com
few days ago at gurufocus.com         
NeuroPace Announces Upcoming Oral Presentation of Data from the Long-Term Post-Approval Study ...
Gurufocus Stories at Macroaxis
few days ago at seekingalpha.com         
NeuroPace refocuses product portfolio reaffirms 2025 revenue guidance
seekingalpha News
few days ago at gurufocus.com         
NeuroPace Announces Refocusing of Product Portfolio
Gurufocus Stories at Macroaxis
few days ago at thelincolnianonline.com         
NeuroPace, Inc. Short Interest Update
news
over a week ago at gurufocus.com         
NeuroPace Inc Stock Price Down 4.25 percent on Mar 27
Gurufocus Stories at Macroaxis
over a week ago at gurufocus.com         
NeuroPace to Present at the 24th Annual Needham Virtual Healthcare Conference
Gurufocus Stories at Macroaxis
over a week ago at www.macroaxis.com         
Acquisition by Martha Morrell of 19850 shares of Neuropace at 12.3 subject to Rule 16b-3
Macroaxis News
over two weeks ago at www.macroaxis.com         
Acquisition by Rebecca Kuhn of 19850 shares of Neuropace at 10.04 subject to Rule 16b-3
Macroaxis News
over two weeks ago at news.google.com         
Cantor Fitzgerald maintains Overweight on NeuroPace stock - Investing.com India
Google News at Macroaxis
over three weeks ago at www.macroaxis.com         
Disposition of 179 shares by Rebecca Kuhn of Neuropace at 4.25 subject to Rule 16b-3
Macroaxis News
over three weeks ago at news.google.com         
Analysts Set Expectations for NeuroPace FY2025 Earnings - MarketBeat
Google News at Macroaxis
over three weeks ago at news.google.com         
Acquisition by Joel Becker of 99200 shares of Neuropace at 10.04 subject to Rule 16b-3
Google News at Macroaxis
over three weeks ago at news.google.com         
Cantor Fitzgerald Forecasts Strong Price Appreciation for NeuroPace Stock - MarketBeat
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about Neuropace that are available to investors today. That information is available publicly through Neuropace media outlets and privately through word of mouth or via Neuropace internal channels. However, regardless of the origin, that massive amount of Neuropace data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Neuropace news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Neuropace relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Neuropace's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Neuropace alpha.

Neuropace Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Disposition of 3200 shares by Martha Morrell of Neuropace at 15.01 subject to Rule 16b-3
01/24/2025
2
Disposition of 100 shares by Martha Morrell of Neuropace at 15.0 subject to Rule 16b-3
01/29/2025
3
Disposition of 200 shares by Martha Morrell of Neuropace at 15.0 subject to Rule 16b-3
01/30/2025
4
NeuroPace Completes Repurchase of 5.3 Million Shares of Its Common Stock from KCK Ltd.
02/20/2025
5
NeuroPace to Present at the Leerink Partners Global Healthcare Conference
03/03/2025
6
NeuroPace Inc. Q4 Earnings Snapshot
03/04/2025
7
Q4 2024 Neuropace Inc Earnings Call Transcript
03/05/2025
8
Cantor Fitzgerald Predicts Higher Earnings for NeuroPace
03/07/2025
9
Acquisition by Joel Becker of 99200 shares of Neuropace at 10.04 subject to Rule 16b-3
03/10/2025
10
Disposition of 179 shares by Rebecca Kuhn of Neuropace at 4.25 subject to Rule 16b-3
03/14/2025
11
Cantor Fitzgerald maintains Overweight on NeuroPace stock - Investing.com India
03/18/2025
12
Acquisition by Rebecca Kuhn of 19850 shares of Neuropace at 10.04 subject to Rule 16b-3
03/20/2025
13
Acquisition by Martha Morrell of 19850 shares of Neuropace at 12.3 subject to Rule 16b-3
03/24/2025
14
NeuroPace to Present at the 24th Annual Needham Virtual Healthcare Conference
03/26/2025
15
NeuroPace Announces Refocusing of Product Portfolio
04/02/2025
16
NeuroPace Announces Upcoming Oral Presentation of Data from the Long-Term Post-Approval Study of the RNS System at the 2025 AAN Annual Meeting
04/03/2025

Complementary Tools for Neuropace Stock analysis

When running Neuropace's price analysis, check to measure Neuropace's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neuropace is operating at the current time. Most of Neuropace's value examination focuses on studying past and present price action to predict the probability of Neuropace's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neuropace's price. Additionally, you may evaluate how the addition of Neuropace to your portfolios can decrease your overall portfolio volatility.
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Fundamental Analysis
View fundamental data based on most recent published financial statements
Transaction History
View history of all your transactions and understand their impact on performance
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges